News
Agilent Attains ‘Angel’ Level Sponsorship with My Green Lab
Agilent Technologies Inc. (NYSE: A) today announced that it has become the first ‘Angel’ level sponsor of My Green Lab, a nonprofit organization dedicated to building a global culture of
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sensorion receives Orphan Drug Designation for OTOF-GT for the treatment of otoferlin gene-mediated hearing loss from the US Food and Drug Administration
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase
Chemed Corporation to Present at the BofA Securities 2022 Virtual Home Care Conference
Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2022 Virtual Home Care Conference on Tuesday, December 5, 2022, at 10:40 AM (ET).
The presentation will
Agilent Deploys Next Generation Explosive Detection System at London Heathrow Airport
Agilent Technologies Inc. (NYSE: A) today announced the deployment of the next generation of alarm resolution technology for checkpoints throughout London Heathrow airport, delivering advanced
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM). GBM is the most common and one of the most
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals
Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program
Charles River Laboratories International, Inc. (NYSE: CRL) recently opened the first Charles River Accelerator and Development Lab (CRADL®) location in Chicago, expanding contract vivarium space
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)
The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
CSL Vifor and Fresenius Kabi today announced that
IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities
IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-News: Formycon Reports its Nine-month Figures for 2022
EQS-News: Expansion of the Management Board of M1 Kliniken AG
Form 8.3 - Mediclinic International plcThe Vanguard Group, Inc.:
EQS-News: Burcon NutraScience Corp.: Burcon Adds Climate Tech Specialist, Aaron T. Ratner to the Board
EQS-News: Burcon NutraScience Corp.: Burcon Announces Results of Shareholder Meeting
ICON plc to Present at the 2022 Evercore ISI HealthCONx Conference
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Evercore ISI